Further in vivo studies discovered using mouse models that inducting CXCR2 was found to worsen steatohepatitis [41] and antagonizing CXCR1 and CXCR2 protected mice from metabolic disease by a modulation of the inflammatory process [42]. This evidence concerns the gene CXCR2 and metabolic disease.